BDF Gestion Sells 6,403 Shares of Abbott Laboratories $ABT

Key Points

• BDF Gestion reduced its stake in Abbott Laboratories by 9.8% in Q2, selling 6,403 shares and maintaining a remaining position of 58,761 shares valued at approximately $7,992,000.
• Abbott Laboratories reported $1.26 EPS for the last quarter, matching analysts' expectations, while its revenue increased by 7.4% to $11.14 billion.
• The company announced a quarterly dividend of $0.59 per share, scheduled for payment on November 17th, with an annualized yield of 1.7%.

BDF Gestion lessened its position in Abbott Laboratories (NYSE:ABT - Free Report) by 9.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,761 shares of the healthcare product maker's stock after selling 6,403 shares during the quarter. Abbott Laboratories comprises about 0.9% of BDF Gestion's investment portfolio, making the stock its 18th biggest position. BDF Gestion's holdings in Abbott Laboratories were worth $7,992,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ABT. Shelton Wealth Management LLC raised its position in shares of Abbott Laboratories by 379.1% during the second quarter. Shelton Wealth Management LLC now owns 9,544 shares of the healthcare product maker's stock valued at $1,298,000 after buying an additional 7,552 shares during the last quarter. AA Financial Advisors LLC increased its stake in Abbott Laboratories by 6.8% in the second quarter. AA Financial Advisors LLC now owns 6,173 shares of the healthcare product maker's stock valued at $840,000 after acquiring an additional 394 shares during the period. Assenagon Asset Management S.A. increased its stake in Abbott Laboratories by 1.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,909,214 shares of the healthcare product maker's stock valued at $259,672,000 after acquiring an additional 33,224 shares during the period. Bell Bank increased its stake in Abbott Laboratories by 48.4% in the second quarter. Bell Bank now owns 3,015 shares of the healthcare product maker's stock valued at $410,000 after acquiring an additional 984 shares during the period. Finally, Elk River Wealth Management LLC bought a new stake in Abbott Laboratories in the second quarter valued at about $729,000. Institutional investors own 75.18% of the company's stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several research analyst reports. Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and upped their price objective for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Wells Fargo & Company reduced their price objective on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a research note on Friday, July 18th. Raymond James Financial dropped their price objective on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research note on Friday, July 18th. Finally, Leerink Partners initiated coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They set a "market perform" rating and a $143.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $145.22.

Abbott Laboratories Stock Performance

Abbott Laboratories stock traded up $0.78 during midday trading on Monday, hitting $136.82. The company's stock had a trading volume of 4,837,007 shares, compared to its average volume of 6,659,060. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The company has a 50-day moving average price of $130.47 and a two-hundred day moving average price of $131.12. The company has a market cap of $238.13 billion, a price-to-earnings ratio of 17.15, a PEG ratio of 2.58 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.7%. Abbott Laboratories's dividend payout ratio is currently 29.57%.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.